Patent ID: 7208141
Filing Date: 2007-04-24
Classification: A61K,A61P,Y02A

Abstract:
1. An inhalable aerosol comprising from about 1 to about 250 mg of purified aztreonam or a pharmaceutically acceptable salt thereof in a dry powder form dissolved in a saline solution per one dose, said aerosol suitable for treatment of pulmonary bacterial infections caused by gram-negative bacteria Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans , and multidrug resistant Pseudomonas aeruginosa, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, bytyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lysinate, maleate, methanesulfonate, nicotinate, 2-napthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate.